All News
ASAS Imaging Recommendations for Suspected Spondyloarthritis
ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).
Read Article
Declining Menopausal Hormone Therapy in Postmenopausal Women
A two decade cross-sectional population study has shown a marked downward trend in menopausal hormone therapy (MHT), with an over 80% reduction, especially in women aged 52 - 65 years.
Read Article
Which One is the Loneliest Number (9.27.2024)
Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.
Read Article
Stratified Cancer Screening in Dermatomyositis
The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.… https://t.co/IQ8JpUMtnn https://t.co/eEM2uuQbKB
Dr. John Cush RheumNow ( View Tweet)
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv
Dr. John Cush RheumNow ( View Tweet)
Pooled data from #PsA (n=914) & #AS (n=372) RCTs looked at outcomes in smokers (37% & 48%). Current or past smoking had NO EFFECT on outcomes (MDA, ACR50, ASAS40, ASDAS), but incr odds of D/C & some SAE (SIE) but not MACE, HZ, VTE https://t.co/WRflSVO3Ig https://t.co/YMI5YCT0QK
Dr. John Cush RheumNow ( View Tweet)
Study of 866 #AS pts shows those w/ lower socioeconomic status (SES) had longer Dx delay, higher BME, more structural damage, & permanent disability (31% vs 13%), compared to high SES AS pts; despite similar use of bDMARDs betw groups. https://t.co/x0dfFACUz9 https://t.co/tOmhE9vGiH
Links:
Dr. John Cush RheumNow ( View Tweet)
Diagnostic delay of 7.4 yrs (median 4yrs) in axSpA. An Int’l IMAS cross-sectional online Pt. survey (2017–22) 5,557 axSpA pts (27 countries). The highest delay in S Africa & lowest in Asia. Longer Dx delay assoc w/ younger age, female, rheumatologist Dx, # HCPs, & Hx uveitis… https://t.co/sqf2uamKG6 https://t.co/JUseWzbwUh
Dr. John Cush RheumNow ( View Tweet)
British Society Guidelines for Managing Behçet’s Disease
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in… https://t.co/4Q1Ac60Dyp https://t.co/Qj3sQQ8SnJ
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory… https://t.co/aITAeYuJxv https://t.co/tAPFfshPSs
Dr. John Cush RheumNow ( View Tweet)
In utero exposure to upadacitinib review w/ 128 maternal exposures & known outcomes; 80 from RCTs & 48 Postmarketing Pregs. From RCTs - 54-46% live births, 24-38% spont. abortions, 21-15% elective Ab, 1-2% ectopics from RCTs & Postmarketing. No evidence of teratogenicity… https://t.co/s3VJspI59V https://t.co/tV48sKyF8x
Dr. John Cush RheumNow ( View Tweet)
Mycophenolate in New-Onset SLE
How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement? A trial of early use of mycophenolate mofetil (MMF), in addition to prednisone and hydroxychloroquine, decreased… https://t.co/TGLGJAg8SA https://t.co/392tItoTn7
Dr. John Cush RheumNow ( View Tweet)
Progression of Undifferentiated Arthritis to Inflammatory Arthritis
https://t.co/Ozr8jPnAcx https://t.co/Jctal4xznB
Dr. John Cush RheumNow ( View Tweet)
EULAR/PReS Still's Disease Management Recommendations
Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3
Dr. John Cush RheumNow ( View Tweet)
Pain Relief with JAK Inhibitors or Anti-TNFs ?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/oIgNxBF518 https://t.co/L9g9MJQbQx
Dr. John Cush RheumNow ( View Tweet)
Adult (133,216) vs Pediatric (955) pts on JAKi - analysis of FAERS shows both @ incr risk for infections & GI AEs. Pediatric pts had more blood and lymphatic disorders, while adults had more CNS and MSK/CTD disorders https://t.co/SKjzANYPSq https://t.co/S6JPYuvSlf
Dr. John Cush RheumNow ( View Tweet)
Lupus nephritis & CKD considerations:
- Non-immune factors: obesity, HTN, Na- or protein-diets, NIDDM, pregnancy, mephrotoxic meds, smoking can add to CKD
- use inhibitors renin–angiotensin & SGLT2 inhibitor w/ proteinuria & low GFR https://t.co/IgL4hpixOm https://t.co/FvmLhf7tQq
Dr. John Cush RheumNow ( View Tweet)
NOR-Gout study shows Non-adherence to urate lowering therapy after 5 years is related to poor gout outcomes. 5-year Observational study of 163 patients showed overall good ULT adherence but nonadherent had more flares (33 vs 10%) & less at target (45 vs 87%)… https://t.co/wHQIRbIoBu https://t.co/eBKL4uRfZc
Dr. John Cush RheumNow ( View Tweet)
UCB & Biogen report positive topline results of Phase 3 RCT of Dapirolizumab Pegol (anti-CD40L) in #SLE & will launch a 2nd Ph 3 RCT in 2024. Phase 3 PHOENYCS GO study was 48 wks of DAP vs PBO in mod-severe SLE w/ BILAG improvement by wk 48 https://t.co/G1DJf31T6t https://t.co/DgpTObIXrB
Dr. John Cush RheumNow ( View Tweet)
Genentech announced top line results of the REGENCY Phase III study of obinutuzumab (Gazyva) in lupus nephritis. 271 LN (class III or IV; +/- V) taking MMF & steroids were given placebo or OBIN for 76 wks. OBIN was superior @ complete renal resp at 76 wks… https://t.co/Um9du7fgxE https://t.co/RRWumnbTuy
Dr. John Cush RheumNow ( View Tweet)